| |
企業(yè)介紹 中英
康臣藥業(yè)集團(tuán)主要從事化學(xué)合成、原料藥、小容量注射劑、顆粒劑、片劑、丸劑、口服液（中藥前處理及提�。�、口服溶液等多種劑型藥品的生產(chǎn)經(jīng)營(yíng)活動(dòng)，并以先進(jìn)的科技水平建立了完善的質(zhì)量保證體系，集團(tuán)各生產(chǎn)基地先后順利通過國(guó)家GMP認(rèn)證。廣東康臣藥業(yè)集團(tuán)在廣州、內(nèi)蒙等地均擁有大型工業(yè)園區(qū)及多條世界一流的制藥生產(chǎn)線，其設(shè)備和技術(shù)水平在行業(yè)中處于領(lǐng)先水平。
Consun Pharmaceutical deals mainly with the production and operation of drugs in a variety of dosage forms, such as chemically synthetic drugs, raw material drugs, small volume injections, granules, tablets, pills, oral liquids (pretreatment and extraction of traditional Chinese drugs) and oral solutions, and has established a sound quality assurance system with advanced technology level. All production bases of the Group have passed the state GMP certification successfully in succession. Guangdong Consun Pharmaceutical has large industrial parks and a number of world-class pharmaceutical production lines in Guangzhou and Inner Mongolia, which are leading in the industry in equipment and technology.
康臣藥業(yè)始終追求產(chǎn)品的高科技、高效能、高品質(zhì)，與國(guó)內(nèi)外多家權(quán)威醫(yī)藥科研機(jī)構(gòu)成立了“康臣腎病藥物研究中心”，具備卓越的產(chǎn)品開發(fā)能力。其中，集團(tuán)腎病系列產(chǎn)品中的主導(dǎo)產(chǎn)品“尿毒清顆粒（無糖型）”作為國(guó)家衛(wèi)生部首個(gè)批準(zhǔn)的治療早中期慢性腎功能衰竭的�？扑幤�，填補(bǔ)了中藥制劑治療CRF的空白，獲國(guó)家專利、國(guó)家中藥保護(hù)品種；“釓噴酸葡胺注射液”（MRI造影劑）填補(bǔ)國(guó)內(nèi)核磁共振診斷成像用藥空白，屬國(guó)家二類新藥，為康臣藥業(yè)首家生產(chǎn)的藥品。以上藥品均已列入國(guó)家基本醫(yī)療保險(xiǎn)藥品和軍隊(duì)合理醫(yī)療藥品目錄。
In a constant pursuit for hi-tech, highly effective and high-quality products, Consun Pharmaceutical has founded the Consun Drug Research Center for Renal Diseases together with several prestigious domestic and foreign medical research institutions, possessing excellent ability to develop products. The Niaoduqing Granules (sugar free), the main product in the Group’s kidney drug series and the first specific drug for early and medium-stage chronic renal failure (CRF) approved by the Ministry of Health of the People’s Republic of China, have filled up a gap in CRF treatment with traditional Chinese medicinal preparations, and become a national patent and a traditional Chinese drug protected by the state. The Gadopentetate Meglumine Injection (MRI contrast medium) has filled up a domestic gap in NMR diagnostic imaging, and is a national Class-II new drug and a drug first produced by Consun Pharmaceutical. The above drugs have been included into the Catalogue of Drugs for Basic National Medical Insurance and the Catalogue of Drugs for Reasonable Military Medical Treatment.
康臣藥業(yè)集團(tuán)已建立覆蓋全國(guó)31個(gè)省市自治區(qū)的營(yíng)銷體系。在鞏固和發(fā)展國(guó)內(nèi)市場(chǎng)的同時(shí)，康臣藥業(yè)不斷開拓國(guó)際市場(chǎng)，目前康臣藥業(yè)各類產(chǎn)品已銷售至港、澳、臺(tái)、東南亞、日本、美國(guó)、加拿大等國(guó)家和地區(qū)。gxgkickz.com
Consun Pharmaceutical has established a marketing network that covers 31 provinces, municipalities and autonomous regions of China. While strengthening and developing its domestic market, Consun Pharmaceutical is always exploring the international market. By now, Consun Pharmaceutical products have been sold to many countries and regions, including Hong Kong, Macao, Taiwan, Southeast Asia, Japan, the U.S. and Canada.
2008年3月31日，康臣藥業(yè)吸收聯(lián)想弘毅1.8億入股資金，戰(zhàn)略重點(diǎn)從原來主要從事產(chǎn)品經(jīng)營(yíng)轉(zhuǎn)向產(chǎn)品經(jīng)營(yíng)、品牌經(jīng)營(yíng)與資本經(jīng)營(yíng)相結(jié)合，標(biāo)志康臣藥業(yè)發(fā)展駛?cè)肟燔嚨馈?br>
On March 31, 2008, Consun Pharmaceutical absorbed equity funds of RMB180 million Yuan from Lenovo Hony, and refocused its strategy from product operation mainly to a combination of product, brand and capital operations, indicating the beginning of its rapid development.
|
|
翻譯樣本 
